EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
EGFR mutations are the first identified targetable driver alterations in advanced non-small cell lung cancer (NSCLC), for which specific epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been developed. These small molecules, administered orally, changed the natural hist...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2022-12-01
|
| Series: | European Medical Journal |
| Online Access: | https://www.emjreviews.com/flagship-journal/article/egfr-mutant-non-small-cell-lung-cancer-state-of-the-art-and-future-perspectives/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|